Purposes: The purpose of the present paper was to prove the efficacy of Percutaneous Cholecystostomy (PC) in the treatment of patients with Acute Cholecystitis (AC) before the COVID-19 pandemic and especially during the pandemic, and to show that it is a safe procedure for patients and healthcare professionals.Materials and Methods: The demographic data of the patients with AC who applied to our hospital, who underwent PC procedure in the 24-month and 12-month period before and during the pandemic, clinical and laboratory data, technical success of PC, clinical response to treatment, length of hospital stay, one-month postprocedural observation, and complications were compared.Results: PC was applied to a total of 124 patients in the pre-pandemic period (52) and pandemic period (72) examined in the study. The median age was 73.5 (25–93) in the pre-pandemic period, and 64 (23–90) in the pandemic period, and the difference between these was found to be significant (p = 0.004). Clinical improvement due to PC was detected in 43 (86%) patients in the pre-pandemic period, and in 61 (84.7%) patients in the pandemic period, no significant differences were detected between the two groups (p = 1.000). The day of hospitalization median value was 3 (1–18) days in pandemic period, and 3 (1–30) days in the pandemic period, and no significant differences were detected between the groups (p = 0.794).ConclusionPC treatment in patients with AC during the pandemic andpre-pandemicc period is effective and safe for both the patient and the healthcare professionals who perform the procedure.The efficacy of percutaneous cholecystostomy in patients with acute cholecystitis before and during the COVID-19 pandemic. Is the percutaneous cholecystostomy procedure safe for patients and healthcare professionals in pandemic conditions?